Please enable Javascript
Zachary Bessette
Zachary Bessette
Articles by Zachary Bessette
ASCO Updates Recommendations for Lutetium-177-PSMA-617 in mCRPC
Zachary Bessette
CRPC
|
December 6, 2023
ASCO has provided a rapid update on its guideline recommendations for 177Lutetium-PSMA-617 in mCRPC.
Read More
Safety, Efficacy of Disitamab Vedotin in Patients With HER2-Positive Locally Advanced or Metastatic UC
Zachary Bessette
Advanced Urothelial Carcinoma
|
December 5, 2023
A recent combined analysis of 2 phase 2 studies indicates that disitamab vedotin has a promising efficacy and safety profile.
Read More
FDA Grants Priority Review to EV Plus Pembrolizumab, Nivolumab Plus Chemotherapy for First-line la/mUC
Zachary Bessette
Advanced Urothelial Carcinoma
|
December 5, 2023
The FDA is granting a priority review for EV/pembro as well as nivo/chemo for the treatment of patients with la/mUC.
Read More
Kidney Cancer: Acting on Disparities and Intervening for Small Renal Masses
Zachary Bessette
SUO 2023
|
November 30, 2023
Drs. Woldu and Pierorazio presented on disparities in RCC care and outcomes as well as appropriate AS in small renal masses.
Read More
Surveillance After Complete Clinical Response From Neoadjuvant Chemotherapy for Bladder Cancer?
Zachary Bessette
SUO 2023
|
November 29, 2023
Dr. McKiernan provided the argument for surveillance in the event of complete clinical response after NAC for MIBC.
Read More
Simultaneous Optimization of Organ Transplant Rates, Urologic Cancer Outcomes
Zachary Bessette
SUO 2023
|
November 29, 2023
Drs. Pierorazio and Eggener moderated a session on simultaneous optimization of organ transplant and GU cancer outcomes.
Read More
Open Versus Robotic RPLND in Clinical Stage 2 Testicular Cancer
Zachary Bessette
SUO 2023
|
November 27, 2023
R-RPLND may offer lower morbidity and improved perioperative outcomes than O-RPLND for patients with CS II testicular cancer.
Read More
Outcomes of Cytoreductive Nephrectomy in Patients Undergoing TKI Versus IO Therapy
Zachary Bessette
SUO 2023
|
November 27, 2023
An analysis compared the outcomes of patients with mRCC who underwent cytoreductive nephrectomy and first-line TKI or IO.
Read More
Partial, Radical Nephrectomy After ICIs for Complex Locally Advanced RCC
Zachary Bessette
SUO 2023
|
November 22, 2023
Surgery for locally advanced RCC may be safe for patients after neoadjuvant durvalumab with or without tremelimumab.
Read More
Tolerability of Lutetium-177-PSMA-617 in Patients With Prostate Cancer, Cytopenia
Zachary Bessette
SUO 2023
|
November 22, 2023
New research sheds light on the safety of (177Lu)–PSMA-617 for patients with mCRPC and poor bone marrow reserve.
Read More
Adverse Events, ER Visits, and Hospitalizations After Lu-PSMA for mCRPC
Zachary Bessette
SUO 2023
|
November 21, 2023
A poster reported on AEs occurring after Lu-PSMA treatment, as well as variables associated with ER visits.
Read More
Trimodality Therapy and Objective Long-term Bladder-Related QOL
Zachary Bessette
SUO 2023
|
November 27, 2023
Recent data suggest good quality of life outcomes for patients with muscle-invasive bladder cancer after trimodality therapy.
Read More
Blood-Based Liquid Biopsy for Diagnosis, Surveillance of Patients With UTUC
Zachary Bessette
SUO 2023
|
November 27, 2023
A study demonstrated evidence for the clinical utility of blood-based liquid biopsy biomarkers for patients with UTUC.
Read More
FDA Approves New Drug Application for Enzalutamide in Earlier Prostate Cancer Setting
Zachary Bessette
Localized
|
November 17, 2023
The FDA approved enzalutamide as the first AR-signaling inhibitor for the treatment of nmCSPC with high-risk BCR.
Read More
Impact of Diabetes on Survival in Patients Undergoing Nephrectomy
Zachary Bessette
2023 IKCS: North America
|
November 10, 2023
A Danish study suggests that diabetes has a significant impact on OS in patients with RCC who undergo nephrectomy.
Read More
International Germline Susceptibility to RCC, Implications for Genetic Screening
Zachary Bessette
2023 IKCS: North America
|
November 10, 2023
A Merit Award-winning abstract offered insight into differences in RCC susceptibility and implications for genetic screening.
Read More
STELLAR-001: Single-Agent Zanzalintinib for Previously Treated Advanced RCC
Zachary Bessette
2023 IKCS: North America
|
November 10, 2023
Zanzalintinib shows promising antitumor activity and manageable toxicity in patients with previously treated advanced ccRCC.
Read More
SABRE Trial Completes Recruitment for 64Cu-SAR-Bombesin Imaging
Zachary Bessette
Advanced Imaging
|
November 7, 2023
Clarity announced that 50 patients have now been imaged with 64Cu-SAR-Bombesin in its US-based diagnostic trial.
Read More
Does the Addition of Lenvatinib to Pembrolizumab Improve Outcomes in Advanced Urothelial Carcinoma?
Zachary Bessette
Advanced Urothelial Carcinoma
|
November 1, 2023
Lenvatinib plus pembrolizumab versus pembrolizumab alone as a first-line therapy for patients with advanced UC.
Read More
Clarity, PSI Launch SAR-bisPSMA Phase 3 Trial
Zachary Bessette
Advanced Imaging
|
October 30, 2023
Clarity Pharmaceuticals has partnered with PSI CRO AG to launch a phase 3 diagnostic trial of SAR-bisPSMA in prostate cancer.
Read More
Load More